Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05632315 · ClinicalTrials.gov registry record · Phase 2
PMT for MDRO Decolonization
A Phase 2 study of Methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT05632315 is a Phase 2 study of Methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 150 participants, below the 15,875-participant average among 5 other Methicillin-resistant Staphylococcus Aureus trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05632315, a Phase 2 study of Methicillin-resistant Staphylococcus Aureus and Pseudomonas Aeruginosa, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant bacteria.
Conditions Studied
Interventions
- DRUG PMT
Study Locations (3)
Georgia
- Emory University - Grady Memorial Hospital - Atlanta
Missouri
- Washington University - St Louis
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05632315
The ClinicalTrials.gov registry entry for NCT05632315 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 15,875-participant average among 5 other Methicillin-resistant Staphylococcus Aureus trials with a reported enrollment target (99% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Methicillin-resistant Staphylococcus Aureus appearing as the primary indexed condition, and to 1 intervention - of which PMT is the first listed.
NCT05632315 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05632315 about?
NCT05632315 is a clinical study titled "PMT for MDRO Decolonization". This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant bacteria.
What is the current status of trial NCT05632315?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-08-19. Estimated completion is 2026-05.
What conditions does trial NCT05632315 study?
This clinical trial studies the following conditions: Methicillin-resistant Staphylococcus Aureus, Pseudomonas Aeruginosa, Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, VRE Infection.
What interventions are being tested in trial NCT05632315?
The interventions under investigation include: PMT (DRUG).
Who is sponsoring clinical trial NCT05632315?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05632315 being conducted?
This trial has 3 study locations across Georgia, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methicillin-resistant Staphylococcus Aureus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
RECRUITING · Phase 4
-
Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus
COMPLETED
-
Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
COMPLETED · NA
-
Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms
COMPLETED
-
Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections
COMPLETED
Explore more on PlainTrial
Methicillin-resistant Staphylococcus Aureus
All registered trials for this condition
Pseudomonas Aeruginosa
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.